| __timestamp | Blueprint Medicines Corporation | CymaBay Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7890000 | 8185000 |
| Thursday, January 1, 2015 | 14456000 | 8871000 |
| Friday, January 1, 2016 | 19218000 | 9645000 |
| Sunday, January 1, 2017 | 27986000 | 12387000 |
| Monday, January 1, 2018 | 47928000 | 14381000 |
| Tuesday, January 1, 2019 | 96388000 | 19238000 |
| Wednesday, January 1, 2020 | 157743000 | 17425000 |
| Friday, January 1, 2021 | 195293000 | 23040000 |
| Saturday, January 1, 2022 | 237374000 | 25116000 |
| Sunday, January 1, 2023 | 295141000 | 51953000 |
| Monday, January 1, 2024 | 359272000 |
In pursuit of knowledge
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Blueprint Medicines Corporation and CymaBay Therapeutics, Inc. offer a fascinating study in contrasts. Over the past decade, Blueprint Medicines has seen its SG&A expenses skyrocket by nearly 3,600%, from $7.9 million in 2014 to $295 million in 2023. In contrast, CymaBay Therapeutics has maintained a more modest increase of 535%, with expenses rising from $8.2 million to $51.9 million over the same period.
While Blueprint's aggressive spending may reflect its rapid growth and expansion strategies, CymaBay's more conservative approach could indicate a focus on lean operations. Investors and industry watchers should consider these trends when evaluating the companies' long-term sustainability and strategic priorities.
Who Optimizes SG&A Costs Better? AbbVie Inc. or Blueprint Medicines Corporation
Comparing SG&A Expenses: AstraZeneca PLC vs CymaBay Therapeutics, Inc. Trends and Insights
BeiGene, Ltd. vs CymaBay Therapeutics, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: Ascendis Pharma A/S vs Blueprint Medicines Corporation
Breaking Down SG&A Expenses: Blueprint Medicines Corporation vs ACADIA Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and PTC Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Agios Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Celldex Therapeutics, Inc.
Breaking Down SG&A Expenses: Amneal Pharmaceuticals, Inc. vs CymaBay Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for CymaBay Therapeutics, Inc. and MannKind Corporation
Who Optimizes SG&A Costs Better? CymaBay Therapeutics, Inc. or Evotec SE